The patented aflo™ platform combines a medical device, user-centred app and a cloud-based data analytics hub, delivering automated inhaler technique training and remote support.

An MHRA approved clinical investigation in 100 patients completed in 2024 demonstrated improved inhaler technique, better symptom control, reduced reliever and healthcare usage.

Pilot studies for children with severe asthma commenced in the US and EU in June 25. Contact us to learn more.